Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.185 USD | -1.20% | -4.69% | -29.25% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
Financials (USD)
Sales 2024 * | 357M | Sales 2025 * | 403M | Capitalization | 924M |
---|---|---|---|---|---|
Net income 2024 * | 43M | Net income 2025 * | 56M | EV / Sales 2024 * | 2.59 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.29 x |
P/E ratio 2024 * |
20.3
x | P/E ratio 2025 * |
16.1
x | Employees | 895 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.76% |
Latest transcript on MiMedx Group, Inc.
1 day | -0.16% | ||
1 week | -1.57% | ||
Current month | -18.70% | ||
1 month | -18.70% | ||
3 months | -24.94% | ||
6 months | +1.79% | ||
Current year | -28.62% |
Managers | Title | Age | Since |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 23-01-26 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 23-07-04 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 20-07-01 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 21-03-07 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 2 M€ | -.--% | ||
0.01% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 6.185 | -1.20% | 355 371 |
24-04-29 | 6.26 | -0.16% | 1,003,507 |
24-04-26 | 6.27 | +0.40% | 604,808 |
24-04-25 | 6.245 | -2.88% | 1,588,525 |
24-04-24 | 6.43 | -1.23% | 648,231 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.62% | 924M | |
-19.49% | 130M | |
-6.57% | 68.37M | |
+5.69% | 60.11M | |
+1.80% | 52.22M |
- Stock Market
- Equities
- MDXG Stock